A Time to Settle; A Time to Fight
This article was originally published in RPM Report
Executive Summary
It seems like an odd time to fight with the government fraud investigators over false claims suits. The public perception of white-collar greed is back in vogue; more money is headed to the fraud investigators at HHS and the Justice Department, top government leaders are putting their public reputations at stake on big cash recoveries, and pharma settlement figures are steadily around $500 million or more.But J&J and Allergan look ready to fight back.
You may also be interested in...
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.